Holen Sie sich die Stockscreener-App
1.27
4.10%
0.05
Handel nachbörslich:
1.26
-0.01
-0.79%
Schlusskurs vom Vortag:
$1.22
Offen:
$1.23
24-Stunden-Volumen:
642.87K
Relative Volume:
1.53
Marktkapitalisierung:
$76.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.56M
KGV:
-1.0855
EPS:
-1.17
Netto-Cashflow:
$-35.28M
1W Leistung:
-15.89%
1M Leistung:
-9.93%
6M Leistung:
-26.59%
1J Leistung:
-56.95%
1-Tages-Spanne:
$1.18
$1.32
1-Wochen-Bereich:
$1.18
$1.52
52-Wochen-Spanne:
$0.8505
$4.42
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corporation
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Vergleichen Sie PDSB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.27 | 76.79M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corporation Aktie (PDSB) Neueste Nachrichten
PDSB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Transcript : PDS Biotechnology CorporationSpecial Call - MarketScreener
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen - Defense World
HC Wainwright Issues Pessimistic Estimate for PDSB Earnings - Defense World
PDS Biotechnology Co. (NASDAQ:PDSB) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Raises Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC Wainwright - Defense World
PDS Biotech expands equity incentive plan By Investing.com - Investing.com Canada
PDS Biotech expands equity incentive plan - Investing.com
PDS Biotechnology Approves Equity Plan Amendment at Meeting - TipRanks
# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock - Investing.com
# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock By Investing.com - Investing.com UK
PDSB Biotechnology's Virtual Event to Discuss Advances in HPV16-Positive HNSCC | PDSB Stock News - GuruFocus
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC - The Manila Times
PDS Biotechnology Corporation to Host Webinar on HPV16-Positive HNSCC and Merck KN-689 Study - Nasdaq
Jane Street Group LLC Invests $58,000 in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Northern Trust Corp Trims Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial By Investing.com - Investing.com South Africa
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - inkl
Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus - TradingView
PDSB: PDS Biotechnology Releases Promising Results from Versamune HPV Studies | PDSB Stock News - GuruFocus
PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO - TipRanks
PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial - Investing.com India
Clinical Trial Breakthrough: PDS Biotech Achieves 30-Month Survival in Advanced Head and Neck Cancer Patients - Stock Titan
PDS Biotechnology files to sell 9.82M shares of common stock for holders - MSN
PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Sh - GuruFocus
PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDS - GuruFocus
PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Shares - GuruFocus
PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDSB Stock News - GuruFocus
Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to “Hold” - Defense World
PDS Biotechnology Corporation (PDSB)’s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial - Insider Monkey
Q2 EPS Estimates for PDS Biotechnology Raised by B. Riley - Defense World
PDS Biotech reports extended survival in HPV cancer study - Investing.com Australia
PDS Biotech reports extended survival in HPV cancer study By Investing.com - Investing.com India
PDS Biotechnology Reports Promising Overall Survival Data for Versamune® HPV Combined with Pembrolizumab in HPV16-Positive Head and Neck Cancer - Nasdaq
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - TradingView
PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential By Investing.com - Investing.com South Africa
PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential - Investing.com
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase - The Manila Times
PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript - MSN
PDS Biotech outlines continued VERSATILE 003 Phase 3 expansion while advancing HPV16-positive head and neck cancer strategy - MSN
Raymond James Financial Inc. Takes $26,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Reports Q1 2025 Progress and Financials - TipRanks
PDS Biotech advances Phase 3 trial, reports Q1 financials By Investing.com - Investing.com Nigeria
PDS Biotechnology: Q1 Earnings Snapshot - Midland Daily News
EMV Capital portfolio company PDS Biotech advances cancer trial - Proactive Investors
PDS Biotech advances Phase 3 trial, reports Q1 financials - Investing.com Australia
Earnings call transcript: PDS Biotech’s Q1 2025 results show reduced losses - Investing.com
Transcript : PDS Biotechnology Corporation, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Finanzdaten der Pds Biotechnology Corporation-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pds Biotechnology Corporation-Aktie (PDSB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Glover Stephen C. | Director |
Feb 28 '25 |
Buy |
1.66 |
15,061 |
25,001 |
78,851 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):